Bilgehan KARADAYI, Müge AKMANSU, Ahmet DİRİER, Özgür AKDEMİR

Amifostinin sitoprotektif etkinliğinin kantitatif tükürük bezi sintigrafisi ile değerlendirilmesi

Çalışmamızın amacı amifostinin ana tükürük bezleri üzerine olan radyokoruyuculuk özelliğini dinamik kantitatif sintigrafik ölçümler ile değerlendirmek ve doğrulamaktır. Çalışmanın dizaynı randomize olmayan klinik çalışmadır. Baş-boyun bölgesine primer veya adjuvan olarak radyoterapi uygulanan 26 baş-boyun kanserli hasta çalışmamıza katıldı. Bir gruba radyoterapi öncesinde amifostin uygulanırken kontrol grubuna ilaç uygulanmadı. Kantitatif sintigrafik parametre olarak wash-out hızı ana değerlendirme ölçütü seçildi ve radyoterapi sonrası değişimler iki grup arasında karşılaştırıldı. Parotis bezi wash-out hızı radyoterapi sonrası 3. ayda amifostin grubunda iyileşme gösterirken kontrol grubunda iyileşme izlenmedi. Submandibüler wash-out hızı kontrol grubunda radyoterapi sonrası 3. ayda daha da kötüleşirken amifostin grubunda değişmedi. Amifostinin ana tükürük bezleri üzerine radyokoruyuculuk özelliği dinamik kantitatif tükürük bezi sintigrafi ile de gözlemlenebilmektedir.

Anahtar Kelimeler:

Tükrük bezleri, Amifostin, Hücre korunması, Baş ve boyun neoplazmları, Radyonüklid görüntüleme, Radyoterapi, Tükrük

Assessment of the cytoprotective efficacy of amifostine with quantitative salivary gland scintigraphy

The main objective of our study was to assess and confirm the radioprotective effect of amifostine in protecting major salivary glands with dynamic quantitative scintigraphic evaluation. The study design was non-randomized clinical trial. There were 26 patients with head and neck cancer who receive primary or adjuvant radiotherapy in the head and neck region. Amifostine administrations were done before radiotherapy in one group while the control group did not take the drug. The primary end-point was wash-out rate as the quantitative scintigraphic parameter and changing patterns after radiotherapy were compared. Parotid wash-out rate showed some healing at the 3rd month of radiotherapy in the amifostine group, but not in the control group. Submandibular wash-out rate showed some worsening at the 3rd month of radiotherapy in the control group, but not in the amifostine group. Radioprotective effect of amifostine in major salivary glands can be observed with the testing tool of dynamic quantitative salivary gland scintigraphy.

Keywords:

Salivary Glands, Amifostine, Cytoprotection, Head and Neck Neoplasms, Radionuclide Imaging, Radiotherapy, Saliva,

PDF

___

1. Roesink JM, Moerland MA, Battermann JJ, et al. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys, 2001;51:938-946.
2. Patt HM, Tyree EB, Straube RL, et al. Technical papers: Cystein protection against X irradiation. Science, 1949; 110: 213-214.
3. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2000; 46: 1105-1108.
4. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 2000; 18: 3339-3345.
5. Buntzel J, Kuttner K, Frohlich D, et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol, 1998; 9: 505-509.
6. Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys, 2000; 48: 1035-1039.
7. Klutmann S, Bohuslavizki KH, Kröger S, et al. Quantitative Salivary Gland Scintigraphy. J Nucl Med Technol, 1999; 27: 20-26.
8. Kosuda S, Satoh M, Yamamoto F, et al. Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys, 1999; 45: 379-384.
9. Olmos RAV, Keus RB, Takes RP, et al. Scintigraphic assessment of salivary function and excretion response in radiation induced injury of the major salivary glands. Cancer, 1994; 73: 2886-2893.
10. McDonald S, Meyerowitz C, Smudzin T, et al.Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys, 1994; 29: 747-754.
11. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol, 2003; 4: 378-381.
12. Clement JJ, Johnson RK. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors. Int J Radiat Oncol Biol Phys, 1982; 8: 539-42.
13. Stewart FA, Rojas A, Denekamp J. Radioprotection of two mouse tumors by WR- 2721 in single and fractionated treatments. Int J Radiat Oncol Biol Phys, 1983; 9: 507-13.
14. McChesney SL, Gillette EL, Dewhirst MW, Withrow SJ. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys, 1986; 12: 1957-63.
15. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol, 2000; 57:113-8.